Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oral LXH254 with or without PDR001 in advanced solid tumors with MAPK pathway alterations
jRCT2080223169Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of naporafenib and spartalizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and melanoma (2 arms), sponsored by Novartis. Primary endpoint: Primary endpoint (assumed). Started Apr 2016; status: completed.
02
Drugs
naporafenibspartalizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on jRCT2080223169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223169.